Stocks To Buy

Looking for stocks that offer both growth potential and steady dividend income? Look no further than these 10 high-growth dividend paying stocks. These companies not only have a history of strong earnings and revenue growth, but also reward their shareholders with regular dividend payments. One standout on the list is Apple Inc. (AAPL), known for its popular iPhones and other tech products. Despite being one of the largest companies in the world, Apple continues to see impressive growth, with its stock ...
Read More About This

Toyota, the renowned automotive giant, is making waves in the financial world with its recent expansion in Arizona. This move not only showcases the company's commitment to growth and innovation, but also presents a promising opportunity for investors to reap steady dividends. The expansion, which includes a $400 million investment to build a new plant in Arizona, is expected to create 1,500 jobs and significantly increase Toyota's production capacity. This is great news for the company and its shareholders, as it ...
Read More About This

Palm Valley Capital Fund recently released their Q2 2025 investor letter, providing valuable insights and opportunities for retail investors. Let's take a look at the key takeaways from this update. The letter focuses on the fund's performance over the past quarter, highlighting a 10.5% return for investors. This outperformed the S&P 500's 7.5% return, showcasing the fund's strong management and strategic investments. With a long-term approach and a focus on quality companies, Palm Valley Capital Fund has consistently delivered solid returns ...
Read More About This

Archer Aviation (ACHR) was hit hard last week as its stock price dropped by over 20%. This sudden decline was due to the news that one of the company's executives had sold off their entire stake in the company. This news came as a surprise to many investors, causing them to question the stability and future of the company. The executive, who had been with Archer Aviation since its early days, sold off their stake for a significant profit. This action ...
Read More About This

Looking for long-term investment opportunities that won't break the bank? Look no further than these 10 non-tech stocks that are poised for growth over the next three years. First on the list is healthcare giant Johnson & Johnson (JNJ), with a diverse portfolio of consumer health products, pharmaceuticals, and medical devices. With a strong track record of increasing dividends and a stable financial standing, JNJ is a solid choice for investors looking for stability and growth potential. Next up is retail giant ...
Read More About This

Indie Semiconductor (INDI) experienced a rough first quarter due to uncertainty surrounding tariffs. The company's stock dropped by over 10% in Q1, causing concern among investors. This decline can be attributed to the ongoing trade tensions between the US and China, as well as other factors affecting the semiconductor industry. Tariffs have been a hot topic in the news lately, and their impact on the stock market is evident. Indie Semiconductor is just one example of a company feeling the effects ...
Read More About This

Apple Inc. (AAPL) has been a hot topic in the market lately, with many investors and analysts wondering if the tech giant's stock price is justified. However, CNBC's Jim Cramer is taking a different approach and asking a more specific question: what exactly are we paying for when we invest in Apple? Cramer points out that Apple's stock has been on a steady rise, reaching a market cap of $2.14 trillion. But he questions what justifies this valuation. Is it the ...
Read More About This

Morgan Stanley, one of the world's leading financial institutions, has recently assumed coverage of Axsome Therapeutics (AXSM) and given it an "overweight" rating. This comes as no surprise to many in the investment world, as Axsome has been making waves with its innovative treatments for neurological disorders. Axsome Therapeutics specializes in developing therapies for central nervous system (CNS) disorders, with a focus on depression and migraines. The company's flagship drug, AXS-05, has shown promising results in treating major depressive disorder and ...
Read More About This